# A Study of CM326 in Subjects With Moderate to Severe Asthma

> **NCT05774340** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 207 (estimated)

## Conditions studied

- Moderate to Severe Asthma

## Interventions

- **DRUG:** CM326
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05774340
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-18
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 207 (ESTIMATED)
- **Last updated:** 2023-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05774340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05774340, "A Study of CM326 in Subjects With Moderate to Severe Asthma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05774340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*